Company intelligence / Profile preview
Foamix Pharmaceuticals Ltd.
Rehovot, Israelfoamix.co.il ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Foamix successfully developed AMZEEQ™ (minocycline) topical foam, 4%, which received FDA approval for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in adults and pediatric patients 9 years of age and older. The company also completed Phase III trials for FMX103 for rosacea treatment and was developing FCD105 for acne.
- Therapeutic areas
- Women's HealthDermatologyOphthalmologyInfectious Diseases
- Modalities
- Topical foam formulationsTopical gel formulations
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
LEO Pharma A/S (formerly Bayer HealthCare AG)Merz Pharmaceuticals, LLCAllergan plcDr. Reddy's
Beyond the preview
Go deeper on Foamix Pharmaceuticals Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Foamix Pharmaceuticals Ltd..